Literature DB >> 11692018

Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study.

L Sjöblom1, H G Hårdemark, A Lindgren, B Norrving, M Fahlén, M Samuelsson, L Stigendal, D Stockelberg, A Taghavi, L Wallrup, J Wallvik.   

Abstract

BACKGROUND AND
PURPOSE: Patients treated with oral anticoagulants (ACs) have an increased risk of intracerebral hemorrhage (ICH), which is more often fatal than spontaneous ICH. Options to reverse the AC effect include intravenous administration of vitamin K, plasma, and coagulation factor concentrate. However, the optimal management of AC-related ICH has not been determined in any randomized trial. In this study, the present management of AC-related ICH was surveyed, and determinants of survival were assessed.
METHODS: We retrospectively reviewed the medical records of all AC-related ICHs at 10 Swedish hospitals during a 4-year period, 1993 to 1996. Survival status after the ICH was determined from the Swedish National population register.
RESULTS: We identified 151 patients with AC-related ICH. Death rates were 53.6% at 30 days, 63.6% at 6 months, and 77.5% at follow-up (mean 3.5 years). The case fatality ratio at 30 days was 96% among patients unconscious on admission (n=27), 80% among patients who became unconscious before active treatment was started (n=15), 55% among patients in whom no special action was taken except withdrawal of AC treatment (n=42), and 28% among patients given active anti-coumarin treatment while they were still conscious (n=64). The case fatality ratio at 30 days was 11% in the group treated with plasma (n=18), 30% in the group treated with vitamin K (n=23), and 39% in the group treated with coagulation factor concentrate (n=23). Within the first 24 to 48 hours after admission, 47% of the patients deteriorated. Choice of therapy to reverse the AC effect differed substantially between the hospitals (P<0.0001), as did the time interval from symptom onset to start of treatment. Multiple logistic regression analysis showed only 2 factors (intraventricular extension of bleeding and ICH volume) that were independently related to case fatality at both 30 days and 6 months. The results were similar when the analysis was restricted to patients who were conscious on admission.
CONCLUSIONS: In AC-related ICH, a progressive neurological deterioration during the first 24 to 48 hours after admission is frequent, and the mortality is high. Choice of therapy to reverse the AC effect differed considerably between the hospitals. There was no evidence that any treatment strategy was superior to the others. A randomized controlled trial is needed to determine the best choice of treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11692018     DOI: 10.1161/hs1101.098523

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  47 in total

Review 1.  Intraventricular fibrinolysis for intracerebral hemorrhage with severe ventricular involvement.

Authors:  Dimitre Staykov; Juergen Bardutzky; Hagen B Huttner; Stefan Schwab
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

2.  [Recommendations of the European Stroke Initiative for the diagnosis and treatment of spontaneous intracerebral haemorrhage].

Authors:  S Külkens; P Ringleb; J Diedler; W Hacke; T Steiner
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214

Review 3.  Should anticoagulation be resumed after intracerebral hemorrhage?

Authors:  Joshua N Goldstein; Steven M Greenberg
Journal:  Cleve Clin J Med       Date:  2010-11       Impact factor: 2.321

4.  Risk of thromboembolism following acute intracerebral hemorrhage.

Authors:  Joshua N Goldstein; Louis E Fazen; Lauren Wendell; Yuchiao Chang; Natalia S Rost; Ryan Snider; Kristin Schwab; Rishi Chanderraj; Christopher Kabrhel; Catherine Kinnecom; Emilie Fitzmaurice; Eric E Smith; Steven M Greenberg; Jonathan Rosand
Journal:  Neurocrit Care       Date:  2008-09-23       Impact factor: 3.210

5.  Treatment of acute intracerebral hemorrhage.

Authors:  Bart M Demaerschalk; Maria I Aguilar
Journal:  Curr Treat Options Neurol       Date:  2008-11       Impact factor: 3.598

Review 6.  Why develop antidotes and reversal agents for non-vitamin K oral anticoagulants?

Authors:  Jeffrey B Washam; Jonathan P Piccini
Journal:  J Thromb Thrombolysis       Date:  2016-02       Impact factor: 2.300

Review 7.  [Intracerebral hemorrhage related to anticoagulant therapy].

Authors:  H B Huttner; E Jüttler; A Hug; M Köhrmann; P D Schellinger; T Steiner
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

8.  The challenge of designing a treatment trial for warfarin-associated intracerebral hemorrhage.

Authors:  Matthew L Flaherty; Opeolu Adeoye; Padmini Sekar; Mary Haverbusch; Charles J Moomaw; Haiyang Tao; Joseph P Broderick; Daniel Woo
Journal:  Stroke       Date:  2009-03-12       Impact factor: 7.914

Review 9.  Evolving management of symptomatic chronic subdural hematoma: experience of a single institution and review of the literature.

Authors:  David Balser; Shaun D Rodgers; Blair Johnson; Chen Shi; Esteban Tabak; Uzma Samadani
Journal:  Neurol Res       Date:  2013-04       Impact factor: 2.448

10.  Effect of aspirin and warfarin on early survival after intracerebral haemorrhage.

Authors:  H Carl Hanger; Valerie J Fletcher; Tim J Wilkinson; Allan J Brown; Chris M Frampton; Richard Sainsbury
Journal:  J Neurol       Date:  2008-02-26       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.